3,4-Dihydroxybenzeneacetic acid/Dopamine ratio
|
Basic information |
| Metabolite name | 3,4-Dihydroxybenzeneacetic acid/Dopamine ratio |
 | N/A |
 |
N/A |
 |
N/A |
| Synonyms | NA |
| No. of studies | 5 |
|
Basic information |
| Metabolite name | 3,4-Dihydroxybenzeneacetic acid/Dopamine ratio |
| N/A |
|
N/A |
|
N/A |
| Synonyms | NA |
| No. of studies | 5 |
|
Relationship between 3,4-Dihydroxybenzeneacetic acid/Dopamine ratio and depression (count: 5) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1138 | Type1 | unpredictable subchronic stress group vs. control group | Hippocampus | Swiss mouse | Up |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M650 | Type3 | high dose of decursin group vs. hispidol control group, after TST | Brain | ICR mouse | Down |
| Study M922 | Type2 | CUMS + high dose of P. orientalis group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M922 | Type2 | CUMS + fluoxetine group vs. CUMS group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M982 | Type2 | adult MDD group, post-treatment vs. baseline | Plasma | Human | Down |